Company intelligence / Profile preview

DurVena

Huntington Beach, California, United Statesdurvena.com ↗

Ownership: Private
Development stage: Preclinical

Overview

DurVena’s Photoactivated Tissue Passivation technology uses Rose Bengal dye and LED light to strengthen venous tissue by increasing collagen crosslinks. Pre-clinical results show a 5x increase in vein stiffness and a 70% reduction in intimal hyperplasia, suggesting significant potential to reduce post-surgical complications such as stenosis and graft failure. The company is targeting initial adoption in CABG procedures with plans to expand into PAD and AV fistula markets[1].

Therapeutic areas: CardiovascularNephrology
Modalities: DeviceNon-pharmacological therapy (Photoactivated Tissue Passivation)
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on DurVena.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DurVena.

Explore the full profile